JP3942846B2 - 組織特異的トランスポーター阻害剤 - Google Patents

組織特異的トランスポーター阻害剤 Download PDF

Info

Publication number
JP3942846B2
JP3942846B2 JP2001188843A JP2001188843A JP3942846B2 JP 3942846 B2 JP3942846 B2 JP 3942846B2 JP 2001188843 A JP2001188843 A JP 2001188843A JP 2001188843 A JP2001188843 A JP 2001188843A JP 3942846 B2 JP3942846 B2 JP 3942846B2
Authority
JP
Japan
Prior art keywords
cdx
tissue
val
prx
pept1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001188843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003002843A5 (enExample
JP2003002843A (ja
Inventor
彰 辻
郁巳 玉井
吉道 崔
伸彦 由井
亨 大谷
賢一 宮本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
National Institute of Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001188843A priority Critical patent/JP3942846B2/ja
Application filed by Japan Science and Technology Agency, National Institute of Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Priority to EP02738767A priority patent/EP1405644A4/en
Priority to CA002451433A priority patent/CA2451433C/en
Priority to PCT/JP2002/006104 priority patent/WO2003000285A1/ja
Priority to AU2002313242A priority patent/AU2002313242B2/en
Publication of JP2003002843A publication Critical patent/JP2003002843A/ja
Priority to US10/742,335 priority patent/US7420029B2/en
Publication of JP2003002843A5 publication Critical patent/JP2003002843A5/ja
Application granted granted Critical
Publication of JP3942846B2 publication Critical patent/JP3942846B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polyethers (AREA)
JP2001188843A 2001-06-21 2001-06-21 組織特異的トランスポーター阻害剤 Expired - Fee Related JP3942846B2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2001188843A JP3942846B2 (ja) 2001-06-21 2001-06-21 組織特異的トランスポーター阻害剤
CA002451433A CA2451433C (en) 2001-06-21 2002-06-19 Oligopeptide transporter 1 inhibitor
PCT/JP2002/006104 WO2003000285A1 (fr) 2001-06-21 2002-06-19 Inhibiteur de transporteur specifique de tissu
AU2002313242A AU2002313242B2 (en) 2001-06-21 2002-06-19 Tissue-specific transporter inhibitor
EP02738767A EP1405644A4 (en) 2001-06-21 2002-06-19 TISSUE-SPECIFIC TRANSPORT HEMMER
US10/742,335 US7420029B2 (en) 2001-06-21 2003-12-19 Tissue-specific transporter inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001188843A JP3942846B2 (ja) 2001-06-21 2001-06-21 組織特異的トランスポーター阻害剤

Publications (3)

Publication Number Publication Date
JP2003002843A JP2003002843A (ja) 2003-01-08
JP2003002843A5 JP2003002843A5 (enExample) 2004-10-28
JP3942846B2 true JP3942846B2 (ja) 2007-07-11

Family

ID=19027864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001188843A Expired - Fee Related JP3942846B2 (ja) 2001-06-21 2001-06-21 組織特異的トランスポーター阻害剤

Country Status (6)

Country Link
US (1) US7420029B2 (enExample)
EP (1) EP1405644A4 (enExample)
JP (1) JP3942846B2 (enExample)
AU (1) AU2002313242B2 (enExample)
CA (1) CA2451433C (enExample)
WO (1) WO2003000285A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
TWI355276B (en) 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633268A1 (de) * 1996-08-19 1998-02-26 Hoechst Ag Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung

Also Published As

Publication number Publication date
US7420029B2 (en) 2008-09-02
EP1405644A1 (en) 2004-04-07
JP2003002843A (ja) 2003-01-08
EP1405644A4 (en) 2005-04-06
AU2002313242B2 (en) 2005-06-16
US20040191211A1 (en) 2004-09-30
CA2451433A1 (en) 2003-01-03
CA2451433C (en) 2007-10-30
WO2003000285A1 (fr) 2003-01-03

Similar Documents

Publication Publication Date Title
KR100483779B1 (ko) 지혈성디펩티드를포함하는약학조성물
KR100700963B1 (ko) 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제
JP3942846B2 (ja) 組織特異的トランスポーター阻害剤
CA2621847A1 (en) Prodrugs of t3 and t4 with enhanced bioavailability
US20250320251A1 (en) Pharmaceutical compositions comprising novel cyclic peptides
JP5778692B2 (ja) 疾病抑制剤
CN107337710A (zh) 一种抗高血压活性肽The‑The‑Pro及应用和药物组合物
CA2203632A1 (en) A chitosan polymer having a specific degree of acetylation
CN100531801C (zh) 聚乙二醇化藤黄酸类前药、其制备方法、制剂及制备药物的用途
JP2008297208A (ja) アンジオテンシンｉ変換酵素阻害剤
CN107337712A (zh) 一种抗高血压活性肽Orn‑Hyp‑Pro及应用和药物组合物
CN107325153A (zh) 一种抗高血压活性肽Citn‑Hyp‑Pro及应用和药物组合物
US20250011364A1 (en) Tumor tissue-penetrating peptide, specifically binding to neuropilin 1, for drug delivery to tumor, and use thereof
US12115222B2 (en) Compositions and methods for improving the solubility of erectile dysfunction therapeutics
US20250144169A1 (en) iRGD-ANALOGS AND RELATED THERAPEUTIC METHODS
EP1740215B1 (en) Thiopeptides for drug delivery
CN114989259A (zh) 一种小分子肽Ped4及应用
WO2024222960A1 (zh) 聚合物-药物偶联物、其中间体及其应用
CN115806583A (zh) 一种两亲性多肽衍生物及其应用
CN112294972A (zh) Psma激活式抗肿瘤前药cpt-y及其制备方法和应用
WO2005077401A1 (fr) Cardiotonique contenant un tripeptide ou un derive de celui-ci en tant qu'ingredient actif
WO2015032981A1 (en) Erythropoietin conjugates having oral bioavailability
JPWO2000025825A1 (ja) Ｄｄｓ化合物及びその測定方法
JPWO2002000734A1 (ja) Ｄｄｓ化合物及びその製造方法

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20031210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070404

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees